A Phase Ib Dose Escalation, Open Label, Multicenter Study Evaluating LDE225 in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients "EDALINE"

Trial Profile

A Phase Ib Dose Escalation, Open Label, Multicenter Study Evaluating LDE225 in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients "EDALINE"

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Sonidegib (Primary) ; Docetaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms EDALINE
  • Most Recent Events

    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
    • 05 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 21 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top